English version Polska wersja
 

Read-Gene - Innovative Genetics

READ-GENE SA is a company of innovative technologies, which aim is to commercialize methods of detection, prevention and treatment of the most common types of malignant tumours.
 
1 2 3
 
 

Co-operation

selvita kcr adamed

About Read-Gene

The company’s special fields are chemoprevention, clinical trials and genetic testing, all complementary fields.

 

In chemoprevention natural and synthetic substances are applied to stop, revert or delay the cancer process. Chemoprevention is Read-Gene’s main field. In order to keep its prevention programme on a possibly natural level, the company has developed the Read-Gene Anticancer Diet, the details of which will be available on a currently constructed company website. In the Read-Gene Anticancer Diet patients are given food with dosaged microelements and vitamins selected according to their genetics to lower the risk of cancer.

 

The object of clinical trials is to ascertain whether a drug, preparation or technology is effective and safe. Read-Gene offers clinical trials to companies, mainly from the medical, pharmaceutical, chemical and biotechnological branches.What is ground-breaking in this programme is the fact that it focuses on patients with a defined genetic profile. In two clinical trials cycles commissioned by pharmaceutical firms Read-Gene managed to recruit the largest number of patients worldwide, for which the company received commendation letters.

 

Genetic testing and genetic/cancer consulting are open to all patients. In December 2008 the company launched a web platform in Polish and English, through which genetic mutation tests can be ordered from all over the world. Genetic testing is an important part of Read-Gene’s work. It allows early diagnosis of cancer susceptibility and, in effect, the timely application of chemoprevention.

 

The company’s intellectual value includes five foreign and six domestic patents, with more patent applications in process.

 

In February 2009 Read-Gene made a debut on the Warsaw Stock Exchange’s New Connect floor, its stock value almost quadrupling over the following 13 months.